BIT (ASX) $10 Billion Deal

Originally posted by Batmansdaughter: ↑

Evansblue

sounds like there is a mix of stories hear being combined into one.

There are several CV studies happening in Australia for vaccines and for antivirals. BIT is working on an antiviral, but there is no guarantee that it is 225, their main drug for HIV. They have other compounds that are viroporin inhibitors, just as 225 is in the case of HIV (it acts on the Vpu protein). They have other compounds that they've used against SARS1 and other RNA viruses that have ion channel inhibitor efficacy. In the case of SARS1, the ion channel proteins are N15 and V25. SARS-Cov-2, the coronavirus that causes COVID-19, also contains these molecules.

China is testing Remdesivir, a failed Ebola antiviral made by Gilead, which did show efficacy against MERS in monkeys. MERS is more distant to SARS-CoV2 than SAR1 is. The drug is undergoing a quick phase 3 type study in both Chine and the US after it was used on compassionate grounds on the first infected patient in the US. He recovered, but we still don't know if it was because of Remdesivir. Let's hope it was.

As you can see, when people speak loosely of HIV antivirals being used presently to treat COVID patients, as well as new ones being tested, and then we have BIT with a highly regarded new HIV antiviral, possibly also being tested on CV (or not), as well as other compounds possibly able to treat the virus, there is plenty of room for mix-up.

China

Expand

Makes sense! All the info we are hearing can make things confusing to digest..but from the research and what i have been reading and recent announcments I do think biotron is in with a very good chance..

Originally posted by Batmansdaughter: ↑

Evansblue

sounds like there is a mix of stories hear being combined into one.

There are several CV studies happening in Australia for vaccines and for antivirals. BIT is working on an antiviral, but there is no guarantee that it is 225, their main drug for HIV. They have other compounds that are viroporin inhibitors, just as 225 is in the case of HIV (it acts on the Vpu protein). They have other compounds that they've used against SARS1 and other RNA viruses that have ion channel inhibitor efficacy. In the case of SARS1, the ion channel proteins are N15 and V25. SARS-Cov-2, the coronavirus that causes COVID-19, also contains these molecules.

China is testing Remdesivir, a failed Ebola antiviral made by Gilead, which did show efficacy against MERS in monkeys. MERS is more distant to SARS-CoV2 than SAR1 is. The drug is undergoing a quick phase 3 type study in both Chine and the US after it was used on compassionate grounds on the first infected patient in the US. He recovered, but we still don't know if it was because of Remdesivir. Let's hope it was.

As you can see, when people speak loosely of HIV antivirals being used presently to treat COVID patients, as well as new ones being tested, and then we have BIT with a highly regarded new HIV antiviral, possibly also being tested on CV (or not), as well as other compounds possibly able to treat the virus, there is plenty of room for mix-up.

China

Expand

Originally posted by Batmansdaughter: ↑

Evansblue

sounds like there is a mix of stories hear being combined into one.

There are several CV studies happening in Australia for vaccines and for antivirals. BIT is working on an antiviral, but there is no guarantee that it is 225, their main drug for HIV. They have other compounds that are viroporin inhibitors, just as 225 is in the case of HIV (it acts on the Vpu protein). They have other compounds that they've used against SARS1 and other RNA viruses that have ion channel inhibitor efficacy. In the case of SARS1, the ion channel proteins are N15 and V25. SARS-Cov-2, the coronavirus that causes COVID-19, also contains these molecules.

China is testing Remdesivir, a failed Ebola antiviral made by Gilead, which did show efficacy against MERS in monkeys. MERS is more distant to SARS-CoV2 than SAR1 is. The drug is undergoing a quick phase 3 type study in both Chine and the US after it was used on compassionate grounds on the first infected patient in the US. He recovered, but we still don't know if it was because of Remdesivir. Let's hope it was.

As you can see, when people speak loosely of HIV antivirals being used presently to treat COVID patients, as well as new ones being tested, and then we have BIT with a highly regarded new HIV antiviral, possibly also being tested on CV (or not), as well as other compounds possibly able to treat the virus, there is plenty of room for mix-up.

China

Expand

No.	Vol.	Price($)
1	131000	2.2¢

No.

Vol.

Price($)

131000

2.2¢

Price($)	Vol.	No.
2.3¢	1295289	4

Price($)

Vol.

No.

2.3¢

1295289

No.	Vol.	Price($)
1	131000	0.022
1	386499	0.021
8	599273	0.020
10	2914214	0.019
10	1719636	0.018

No.

Vol.

Price($)

131000

0.022

386499

0.021

599273

0.020

2914214

0.019

1719636

0.018

Price($)	Vol.	No.
0.023	1295289	4
0.024	112849	1
0.025	150000	1
0.027	169508	3
0.029	316026	1

Price($)

Vol.

No.

0.023

1295289

0.024

112849

0.025

150000

0.027

169508

0.029

316026

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $19.85M

Open	High	Low	Value	Volume
2.2¢	2.3¢	2.1¢	$27.02K	1.223M

$10 Billion Deal, page-5697

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

James Bay latest lithium player to pivot to other metals amidst lithium slump

Battery Age Minerals gets set to capitalise on critical mineral demand

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$10 Billion Deal, page-5697

Top Stories

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

James Bay latest lithium player to pivot to other metals amidst lithium slump

Battery Age Minerals gets set to capitalise on critical mineral demand

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News